Mometasone furoate monohydrate

DRUG3 trials

Sponsors

Allergy Therapeutics (UK) Limited, JHSPH Center for Clinical Trials, Merck Sharp & Dohme LLC

Conditions

AsthmaRhinitisRhinitis, Allergic, SeasonalSeasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen exposureSinusitis

Phase 3

Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

CompletedNCT02478398

Merck Sharp & Dohme LLCRhinitis, Allergic, Seasonal

Start: 2015-07-20End: 2018-11-19Updated: 2019-09-06

A long-term, double-blind, randomised, placebo-controlled clinical trial to investigate the efficacy and safety of PQ Grass 27600 SU in children and adolescents with seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen exposure

RecruitingCTIS2023-508520-36-00

Allergy Therapeutics (UK) LimitedSeasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen exposure

Start: 2024-09-06Target: 358Updated: 2025-12-09

Phase 4

Study of Asthma and Nasal Steroids

CompletedNCT01118312

JHSPH Center for Clinical TrialsAsthma, Rhinitis, Sinusitis

Start: 2010-09-30End: 2015-06-30Updated: 2015-11-30

Related Papers

Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis.

2021-12-093 citations

Sublingual Versus Subcutaneous Immunotherapy for Allergic Rhinitis: What Are the Important Therapeutic and Real-World Considerations?

2020-06-1615 citations

Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial.

2020-04-1543 citations